Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV Galidesivir in Healthy Subjects
NCT03800173Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Marburg virus disease (MVD) comparing Galidesivir with Placebo (2 arms). Primary endpoint: Number of Participants Experiencing Adverse Events at 23 days. Started Dec 2018; status: completed.
02
Drugs
galidesivir
03
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT03800173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800173.